R&D
Pipeline
Proceed Domestic and Global Clinical Trials sequentially → Aim to release New Drug in 2025
| Pipelines | Indication | Discovery | Pre-Clinical | PhaseⅠ | PhaseⅡ | PhaseⅢ | NDA | |
|---|---|---|---|---|---|---|---|---|
|
Metabolic Anticancer Therapy |
ASCA101(IntraVenous) | Solid Cancer |
2021 3Q Domestic Phase I Entry The beginning of 2022 Clinical trial will be started in US |
|||||
| ASCA101(New Formulation) | ||||||||
| MF02 | ||||||||
|
Anticancer Combi Therapy |
ASCA101 / MF02 + Existing Anticancer Drug |
Refractory Cancer |
|
|||||
|
Palliative Anticancer Therapy |
MF03 | Cancer Acidosis |
|
|||||
| MF04 | Cachexia |
|
||||||